Skip to content

Biofeedback Therapy Versus Botox Injection in Treatment of Dyssynergic Defecation.

Biofeedback Versus Botox Injection in Treatment of Dyssynergic Defecation (Randomized Controlled Trial)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06724250
Enrollment
78
Registered
2024-12-09
Start date
2023-08-01
Completion date
2024-09-30
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructed Defaecation Syndrome

Brief summary

assessment the Improvement symptoms of obstructed defecation after biofeedback training versus botulinum toxin injection

Detailed description

This is a randomized controlled trial including 78 patients diagnosed with obstructed defecation syndrome confirmed by detailed history talking, full clinical examination, anorectal manometry and defecography. Included patients divided into two equal groups: first group ( biofeedback therapy group) patients recieved biofeedback therapy for six sessions over one month, the second group:( botulinum toxin group) received botulinum toxin injection 100 IU in buborectalis muscle. The primary outcome is improvement of symptoms after one year

Interventions

Biofeedback therapy involves the use of specialized equipment to provide real-time feedback on pelvic floor muscle activity. Participants are trained to improve muscle coordination and relaxation through guided exercises, targeting the resolution of dyssynergic defecation.

Botulinum toxin is injected into the pelvic floor muscles to reduce muscle overactivity and improve coordination, aiming to relieve symptoms of dyssynergic defecation.

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients of both genders * age of 18 years or older * fulfillment of the Rome 3 constipation criteria for the past 3 months, symptom onset as a maximum six months prior to diagnosis, patients suffer from prolonged, incomplete and challenging evacuation

Exclusion criteria

* Anismus cases with secondary reason for constipation * patients who undergone anorectal surgery Patients with colonic inertia * conditions that make biofeedback training impossible * cases with primary illness causing constipation as hypothyroidism

Design outcomes

Primary

MeasureTime frameDescription
Improvement of symptoms of constipation for one year follow upOne year* Follow-up was conducted for about 1 year as regard the improvement in bowel habits. * Patients was asked to fill up a symptom questionnaire (Wexner constipation score with a maximum score of 30 and a minimum of 0) following the therapeutic procedure The wexner constipation score : include 8-item questionnaire about bowel movements frequency, anal pain during evacuation, abdominal pain, incomplete evacuation, time taken for evacuation per attempt, number of attempts for a successful bowel movement in the previous 24 hours, type of assistance for defecation, and duration of constipation. All items are scored from 0 to 4 except for the type of assistance for defecation, which is scored from 0 to 2.The clinical improvement was chosen when there was decrease in the score.

Secondary

MeasureTime frameDescription
Improvement of pain for one year follow upOne yearPain improvement on the visual analogue scale is from 0 to 10, where 0 means no pain and 10 means the worst pain.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026